Hematology

FDA has granted sonrotoclax priority review for relapsed mantle cell lymphoma, showcasing promising trial results.

A study reveals a U-shaped relationship between BMI and CAR T-cell therapy outcomes in multiple myeloma (MM), highlighting the impact of overweight status on efficacy.

AI, especially deep learning applied to blood smear imaging, can greatly improve the speed and accuracy of leukemia detection and subtype classification.

The analysis found that zanubrutinib provides similar progression-free survival to fixed-duration venetoclax plus ibrutinib but with consistently fewer serious side effects, suggesting a more favorable overall safety profile.

As novel multiple myeloma therapies enter the relapsed and refractory treatment landscape, safety is a key consideration, says Hearn Jay Cho, MD, PhD.

Clark Alsfeld, MD, discusses how telemedicine, pharmacists, and evolving policies help overcome financial and geographic barriers in oncology care.

Research challenges age cut-offs in AML treatment, advocating for flexible, individualized approaches based on continuous age assessment.

The FDA approved daratumumab and hyaluronidase-fihj (Darzalex Faspro), offering a new treatment for high-risk smoldering multiple myeloma.

Marcus Flores, PharmD, BCPS, BCOP, discusses the vital role of pharmacists in multidisciplinary cancer care, exploring collaboration, patient-centered strategies, and AI.

Despite improved selectivity, real-world data point to persistent cardiovascular challenges even with next-generation BTKi therapies.

Experts at AMCP Nexus 2025 highlighted how real-world data can improve CAR T-cell therapy access and outcomes.

Marc S. Raab, MD, PhD, discusses the different ways that combination therapy that includes teclistamab can benefit patients with multiple myeloma.

A new analysis suggests links between ZRSR2 loss and JAK2 V617R disease progression are indirect and complex.

Cardiac adverse events were lower among patients taking zanubrutinib compared with ibrutinib in the real-world setting.

Myeloproliferative neoplasms–unclassifiable (MPN-U), show distinct genetic and clinical patterns that differentiate them from essential thrombocythemia.

Serum biochemical fingerprints can stratify chronic lymphocytic leukemia (CLL) outcomes and uncover heterogeneity within molecularly defined low-risk disease.

The FDA approved revumenib for relapsed/refractory (R/R) acute myeloid leukemia, offering a new targeted therapy option for patients with NPM1 mutations.

The FDA has approved belantamab mafodotin for third-line or later multiple myeloma based on DREAMM-7 trial data.

A novel combination therapy enhances the effectiveness of proteasome inhibitors against acute myeloid leukemia (AML), improving survival rates in preclinical models.

Venetoclax plus bortezomib and dexamethasone improved PFS in relapsed/refractory multiple myeloma, especially in patients with BCL2high disease.

The LINKER-SMM1 trial shows promising results for linvoseltamab in treating high-risk smoldering multiple myeloma with a favorable safety profile, notes Paula Rodríguez-Otero, MD, PhD.

Experts discuss the importance of initiating blinatumomab treatment for acute lymphoid leukemia in academic centers for optimal patient care.

Kelley L. Julian, PharmD, BCOP, discusses optimizing myeloma care, addressing barriers in access to intravenous immunoglobulin and innovative therapies at Huntsman Cancer Institute.

Nanopore sequencing of chronic lymphocytic leukemia (CLL) may be a particularly good fit in under-resourced areas due to its lower cost and smaller laboratory footprint.

Rilzabrutinib (Wayrilz; Sanofi) may improve immune thrombocytopenia (ITP) outcomes, enable early intervention, and enhance patient quality of life.